CRBP - Corbus Pharmaceuticals Holdings, Inc.
7.69 +0.01 (0.13%)
After hours: 5:11PM EDT
| Previous Close | 7.26 |
| Open | 7.23 |
| Bid | 7.61 x 3200 |
| Ask | 7.68 x 1800 |
| Day's Range | 7.23 - 7.73 |
| 52 Week Range | 4.50 - 9.11 |
| Volume | 1,769,755 |
| Avg. Volume | 1,669,068 |
| Market Cap | 494.555M |
| Beta (3Y Monthly) | 2.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.98 |
| Earnings Date | Aug 14, 2017 - Aug 18, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.86 |
- ACCESSWIRE•19 minutes ago
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 21, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corbus Pharmaceuticals ...
- GlobeNewswire•1 hour ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corbus Pharmaceuticals Holdings, Inc. – CRBP
Pomerantz LLP is investigating claims on behalf of investors of Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or the “Company”) (NASDAQ: CRBP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Corbus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On February 28, 2019, an article entitled “Corbus Has Ties to Suspect Investors And A History of Failed Clinical Trials for Lenabasum” was published on the website Seeking Alpha. The article expressed the belief that lenabasum, Corbus’s lead product candidate, “has failed every trial,” “has a history of negative clinical data,” and “is likely to fail in the company’s pivotal trial in Scleroderma and Systemic Sclerosis (SSc) and Phase 2b trial in cystic fibrosis.” The article further alleged “ties between Corbus .
- GlobeNewswire•1 hour ago
CORBUS PHARMACEUTICALS HOLDINGS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts against Corbus Pharmaceuticals Holdings, Inc.
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or the “Company”) (CRBP) in the United States District Court for the District of Massachusetts on behalf of those who purchased or acquired the securities of Corbus between November 14, 2016 and February 28, 2019, inclusive (the “Class Period”). Investors who purchased shares of Corbus Pharmaceuticals Holdings, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. If you have incurred losses in the shares of Corbus Pharmaceuticals Holdings, Inc., you may, no later than May 13, 2019, request that the Court appoint you lead plaintiff of the proposed class.
- GlobeNewswire•3 hours ago
Bronstein, Gewirtz & Grossman, LLC Class Action Update: BPI, CRBP & NIO
NEW YORK, March 21, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following.
- GlobeNewswire•7 hours ago
SHAREHOLDER ALERT: VALE WRCDF NIO CRBP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, March 21, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- ACCESSWIRE•yesterday
SHAREHOLDER ALERT: CAG CVS CRBP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / March 20, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you ...
- ACCESSWIRE•yesterday
CLASS ACTION UPDATE for CAG, UMC and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / March 20, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
- ACCESSWIRE•yesterday
Bronstein, Gewirtz & Grossman, LLC Class Action Reminder: BPI, CRBP & NIO
NEW YORK, NY / ACCESSWIRE / March 20, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...
- ACCESSWIRE•2 days ago
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 19, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corbus Pharmaceuticals ...
- GlobeNewswire•2 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ASTE, CAG, INGN and CRBP
NEW YORK, March 19, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- Motley Fool•2 days ago
Here's Why Corbus Pharmaceuticals Is on the Move Today
A presentation reminded investors of the potential in the biotech's endocannabinoid candidates.
- GlobeNewswire•2 days ago
CLASS ACTION UPDATE for AMRN, CNDT, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, March 19, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of CRBP earnings conference call or presentation 12-Mar-19 12:30pm GMT
Full Year 2018 Corbus Pharmaceuticals Holdings Inc Earnings Call
- Zacks•3 days ago
Is Corbus Pharmaceuticals Holdings (CRBP) Stock Outpacing Its Medical Peers This Year?
Is (CRBP) Outperforming Other Medical Stocks This Year?
- GlobeNewswire•4 days ago
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DBVT, AMRN, WTW and CRBP
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.
- GlobeNewswire•6 days ago
SHAREHOLDER ALERT: DBVT VALE SVXY CRBP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, March 15, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- ACCESSWIRE•6 days ago
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Class Action Against Corbus Pharmaceuticals Holdings, Inc. (CRBP) and Lead Deadline: May 13, 2019
NEW YORK, NY / ACCESSWIRE / March 15, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Corbus Pharmaceuticals Holdings, Inc. ("Corbus" ...
- GlobeNewswire•6 days ago
CRBP CLASS ACTION ALERT: Hagens Berman Alerts Corbus Pharmaceutical Holdings (NASDAQ: CRBP) Investors to May 13, 2019 Lead Plaintiff Deadline
SAN FRANCISCO, March 15, 2019 -- Hagens Berman Sobol Shapiro LLP alerts investors in Corbus Pharmaceutical Holdings, Inc. (NASDAQ: CRBP) to the May 13, 2019 Lead Plaintiff.
- Business Wire•7 days ago
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Corbus Pharmaceuticals Holdings, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Corbus Pharmaceuticals Holdings, Inc. investors (“Corbus” or the “Company”) (NASDAQ: CRBP) concerning the Company and its officers’ possible violations of federal securities laws. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On February 28, 2019, an article was published on Seeking Alpha alleging that Corbus “has ties to investors convicted of or alleged to have committed securities fraud” and that its drug candidate, lenabasum, is believed to have “failed its major trials in [systemic sclerosis] and [cystic fibrosis].” On this news, shares of Corbus fell $1.32 per share or nearly 16% to close at $6.94 per share on February 28, 2019, thereby injuring investors.
- Zacks•7 days ago
Corbus Pharmaceuticals (CRBP) Upgraded to Strong Buy: Here's Why
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire•7 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MAXR, BRS, WTW and CRBP
NEW YORK, March 14, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- ACCESSWIRE•7 days ago
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Class Action Against Corbus Pharmaceuticals Holdings, Inc. (CRBP) and Lead Plaintiff Deadline: May 13, 2019
NEW YORK, NY / ACCESSWIRE / March 14, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Corbus Pharmaceuticals Holdings, Inc. ("Corbus" ...
